Overview

Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Chemotherapy is given after curative surgery for pancreas cancer to try to improve cure rates. There are two choices of chemotherapy which are currently considered equal treatments: gemcitabine or 5-fluorouracil (5FU). This study is trying to determine if one of two standard chemotherapies is better than the other depending on whether patients have high or low human equilibrative nucleoside transporter 1 (hENT1). hENT1 is a protein that is found in varying amounts on pancreas cancers.
Phase:
N/A
Details
Lead Sponsor:
AHS Cancer Control Alberta
Treatments:
Fluorouracil
Gemcitabine
Pancreatin
Pancrelipase